...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Translational Medicine >Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources
【24h】

Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources

机译：临床造血细胞来源中内皮祖细胞的免疫表型和菌落计数分析之间没有相关性

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The discovery of adult endothelial progenitor cells (EPC) offers potential for vascular regenerative therapies. The expression of CD34 and VEGFR2 by EPC indicates a close relationship with haematopoietic progenitor cells (HPC), and HPC-rich sources have been used to treat cardiac and limb ischaemias with apparent clinical benefit. However, the laboratory characterisation of the vasculogenic capability of potential or actual therapeutic cell autograft sources is uncertain since the description of EPC remains elusive. Various definitions of EPC based on phenotype and more recently on colony formation (CFU-EPC) have been proposed. Methods We determined EPC as defined by proposed phenotype definitions (flow cytometry) and by CFU-EPC in HPC-rich sources: bone marrow (BM); cord blood (CB); and G-CSF-mobilised peripheral blood (mPB), and in HPC-poor normal peripheral blood (nPB). Results As expected, the highest numbers of cells expressing the HPC markers CD34 or CD133 were found in mPB and least in nPB. The proportions of CD34+ cells co-expressing CD133 is of the order mPB>CB>BM≈nPB. CD34+ cells co-expressing VEGFR2 were also most frequent in mPB. In contrast, CFU-EPC were virtually absent in mPB and were most readily detected in nPB, the source lowest in HPC. Conclusion HPC sources differ in their content of putative EPC. Normal peripheral blood, poor in HPC and in HPC-related phenotypically defined EPC, is the richest source of CFU-EPC, suggesting no direct relationship between the proposed EPC immunophenotypes and CFU-EPC potential. It is not apparent whether either of these EPC measurements, or any, is an appropriate indicator of the therapeutic vasculogenic potential of autologous HSC sources.
机译：背景技术成人内皮祖细胞（EPC）的发现为血管再生疗法提供了潜力。 EPC的CD34和VEGFR2的表达表明它与造血祖细胞（HPC）密切相关，并且富含HPC的来源已被用于治疗心脏和肢体缺血，具有明显的临床益处。然而，由于对EPC的描述仍然难以捉摸，因此潜在的或实际的治疗性细胞自体移植物的血管生成能力的实验室表征尚不确定。已经提出了基于表型的EPC的各种定义，以及最近关于菌落形成的各种定义（CFU-EPC）。方法我们在富含HPC的来源中确定了拟议的表型定义（流式细胞仪）和CFU-EPC定义的EPC。脐带血（CB）;和G-CSF动员的外周血（mPB），以及HPC贫乏的正常外周血（nPB）。结果如预期的，在mPB中发现表达HPC标记CD34或CD133的细胞数量最多，而在nPB中发现最少。共表达CD133的CD34 + 细胞的比例为mPB> CB>BM≈nPB。共表达VEGFR2的CD34 + 细胞在mPB中也最常见。相反，mFU中实际上不存在CFU-EPC，而nPB中最容易检测到CFU-EPC，而HPC中的来源最低。结论HPC来源的推定EPC含量不同。正常的外周血，在HPC和与HPC相关的表型定义的EPC中较差，是CFU-EPC的最丰富来源，表明所提出的EPC免疫表型与CFU-EPC潜力之间没有直接关系。这些EPC测量值或任何EPC测量值是否是自体HSC来源的治疗性血管生成潜力的适当指标尚不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号